Advertisement
Screener

CEL-SCI CORPORATION (CVM) Graph

CVM Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue (m); Research and development $3.65M; Operating expenses $5.56M; Income tax (m).
  • 2026-03-31: Revenue (m); Research and development $3.77M; Operating expenses $5.33M; Income tax (m).
  • 2025-12-31: Revenue (m); Research and development $3.68M; Operating expenses $5.37M; Income tax (m).
  • 2025-06-30: Revenue (m); Research and development $3.74M; Operating expenses $5.49M; Income tax (m).

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$3.65M$5.56M(m)-$5.67M
2026-03-31(m)$3.77M$5.33M(m)-$5.47M
2025-12-31(m)$3.68M$5.37M(m)-$5.47M
2025-06-30(m)$3.74M$5.49M(m)-$5.66M
2025-03-31(m)$4.01M$6.39M(m)-$6.57M
2024-12-31(m)$4.43M$6.89M(m)-$7.07M
2024-06-30(m)$4.70M$6.67M(m)-$6.86M
2024-03-31(m)$4.63M$7.08M(m)-$7.24M
2023-12-31(m)$4.35M$6.49M(m)-$6.71M
2023-06-30(m)$5.73M$8.18M(m)-$8.37M
2023-03-31(m)$6.08M$8.18M(m)-$8.34M
2022-12-31(m)$5.39M$7.65M(m)-$7.85M
2022-06-30(m)$6.29M$8.72M(m)-$9.63M
2022-03-31(m)$6.52M$9.55M(m)-$9.82M
2021-12-31(m)$6.08M$8.84M(m)-$8.78M
2021-06-30(m)$7.18M$10.46M(m)-$8.94M
2021-03-31(m)$5.22M$8.53M(m)-$11.28M
2020-12-31(m)$5.41M$8.73M(m)-$7.94M
2020-06-30(m)$3.97M$7.16M(m)-$10.28M
2020-03-31(m)$4.46M$7.02M(m)-$9.07M
2019-12-31(m)$4.25M$6.89M(m)-$5.53M
2019-06-30(m)$2.97M$5.32M(m)-$12.08M
2019-03-31(m)$2.83M$4.46M(m)-$6.45M
2018-12-31(m)$3.47M$5.16M(m)$1.25M
2018-06-30(m)$2.43M$4.17M(m)-$6.01M
2018-03-31(m)$2.96M$4.34M(m)-$4.71M
2017-12-31(m)$2.33M$5.03M(m)-$6.19M
2017-06-30(m)$3.18M$4.78M(m)-$4.46M
2017-03-31(m)$6.58M$7.92M(m)-$8.43M
2016-12-31(m)$3.55M$4.96M(m)$3.52M
2016-09-30(m)(m)$6.74M(m)(m)
2016-06-30(m)$4.36M$6.04M(m)-$3.86M
2016-03-31(m)$4.15M$5.83M(m)-$8.86M
2015-12-31(m)$4.69M$5.33M(m)$2.33M
2015-09-30(m)(m)$7.80M(m)(m)
2015-06-30(m)$5.73M$8.11M(m)-$4.43M
2015-03-31(m)$5.08M$7.48M(m)-$12.56M
2014-12-31(m)$4.85M$9.66M(m)-$7.85M
2014-09-30$67.82K(m)$8.58M(m)-$7.22M
2014-06-30$15.91K$4.45M$6.92M(m)-$2.44M
2014-03-31$67.16K$4.15M$6.29M(m)-$13.37M
2013-12-31$113.14K$4.02M$6.05M(m)-$4.33M
2013-09-30$15.45K(m)$5.09M(m)-$1.70M
2013-06-30$113.73K$3.77M$5.63M(m)-$4.45M
2013-03-31$15.40K$2.52M$4.26M(m)-$713.37K
2012-12-31$15.00K$2.92M$5.06M(m)-$2.31M
2012-09-30$108.04K(m)$4.43M(m)-$2.57M
2012-06-30$35.00K$2.47M$4.25M(m)-$835.45K
2012-03-31$106.54K$2.59M$4.37M(m)-$8.49M
2011-12-31$5.02K$2.46M$4.45M(m)-$3.58M
2011-09-30$172.12K(m)$3.90M(m)-$2.32M
2011-06-30$77.40K$2.92M$4.92M$0.00-$3.11M
2011-03-31$43.81K$3.04M$5.14M(m)-$14.03M
2010-12-31$662.82K$3.26M$4.98M(m)-$6.25M
2010-06-30$30.90K$1.59M$3.42M$0.00-$601.12K

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesNet income
2026-03-31(m)$7.44M$10.69M-$10.94M
2025-03-31(m)$8.44M$13.29M-$13.65M
2024-03-31(m)$8.98M$13.56M-$13.95M
2023-03-31(m)$11.48M$15.83M-$16.20M
2022-03-31(m)$12.61M$18.40M-$18.61M
2021-03-31(m)$10.64M$17.26M-$19.22M
2020-03-31(m)$8.71M$13.91M-$14.60M
2019-03-31(m)$6.30M$9.62M-$5.20M
2018-03-31(m)$5.29M$9.36M-$10.90M
2017-03-31$34.43K$10.13M$12.88M-$4.91M
2016-03-31$53.75K$8.84M$11.16M-$6.52M
2015-03-31(m)$9.97M$18.09M-$20.40M
2014-03-31(m)$8.17M$12.34M-$17.70M
2013-03-31(m)$5.44M$9.31M-$3.02M
2012-03-31(m)$0.00$8.82M-$12.08M
2011-03-31(m)$6.31M$10.12M-$20.28M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$11.09M$16.25M(m)-$16.60M
2025-06-30(m)$12.18M$18.78M(m)-$19.31M
2024-06-30(m)$13.68M$20.23M(m)-$20.81M
2023-06-30(m)$17.20M$24.01M(m)-$24.56M
2022-06-30(m)$18.89M$27.11M(m)-$28.24M
2021-06-30(m)$17.82M$27.72M(m)-$28.16M
2020-06-30(m)$12.68M$21.07M(m)-$24.88M
2019-06-30(m)$9.27M$14.94M(m)-$17.29M
2018-06-30(m)$7.71M$13.54M(m)-$16.91M
2017-06-30$51.82K$13.31M$17.66M(m)-$9.37M
2016-06-30$183.73K$13.21M$17.19M(m)-$10.38M
2015-06-30(m)$15.70M$26.68M(m)-$24.83M
2014-06-30(m)$12.63M$19.26M(m)-$20.14M
2013-06-30(m)$9.21M$14.94M(m)-$7.47M
2012-06-30(m)$7.52M$13.07M(m)-$12.91M
2011-06-30$784.04K$9.23M$15.04M$0.00-$23.39M
2010-06-30$91.50K$7.73M$13.06M$0.00$17.81M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesNet income
2025-09-30(m)$15.89M$24.81M-$25.41M
2024-09-30(m)$18.16M$26.35M-$26.92M
2023-09-30(m)$22.47M$31.48M-$32.37M
2022-09-30(m)$25.36M$36.06M-$36.70M
2021-09-30(m)$23.11M$36.19M-$36.36M
2020-09-30(m)$17.84M$29.54M-$30.26M
2019-09-30(m)$12.66M$20.66M-$22.13M
2018-09-30(m)$10.91M$17.25M-$31.84M
2017-09-30(m)$15.61M$21.41M-$14.36M
2016-09-30(m)$17.45M$23.93M-$11.51M
2015-09-30(m)$19.19M$33.05M-$34.69M
2014-09-30$264.03K$15.27M$25.93M-$27.35M
2013-09-30$159.58K$12.68M$20.03M-$9.17M
2012-09-30$254.61K$10.37M$17.50M-$15.48M
2011-09-30$956.15K$11.75M$18.94M-$25.71M
2010-09-30(m)$11.91M$18.71M$10.48M
2009-09-30(m)$6.01M$12.10M-$40.91M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Quince Therapeutics, Inc. (QNCX)United States$0.031B
aTYR PHARMA INC (ATYR)United States$0.033B-0.98
Estrella Immunopharma, Inc. (ESLA)United States$0.020B
Jasper Therapeutics, Inc. (JSPR)United States$0.020B-0.37
Scilex Holding Co (SCLX)United States$0.042B-0.14
Metagenomi Therapeutics, Inc. (MGX)United States$0.044B-0.48
BioCardia, Inc. (BCDA)United States$0.016B
DYADIC INTERNATIONAL INC (DYAI)United States$0.016B
Passage BIO, Inc. (PASG)United States$0.015B-0.43
LeonaBio, Inc. (LONA)United States$0.047B-0.61